Apollomics (APLM) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Apollomics
Is Apollomics a buy right now? The alternative data says hold. This APLM stock analysis is built on the 25+ alternative data signals AltIndex tracks on Apollomics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $22.08 with a $68M market cap.
The soft spots over the past 90 days: web traffic down 11.9% to 2K monthly visits. The rest of the signal set is holding steady, which keeps APLM at a hold rather than a sell.
APLM’s broader alt-data profile also covers headcount (25 employees, according to LinkedIn), and X followers (170). Every signal links to its own page with full history, the APLM technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on APLM is just below.
Apollomics AI Stock Analysis
Apollomics is a company engaged in the field of biotechnology, focused on innovative drug discovery and development to address critical unmet medical needs. The company's mission is to bring novel therapies to patients and revolutionize the treatment landscape, particularly in the oncology sector.
Analysis generated August 31, 2026.
Recent Apollomics Stock Alerts
|
Apollomics | September 11 Price is up by 6.5% in the last 24h. |
|
Apollomics | September 8 Price is down by -6.8% in the last 24h. |
|
Apollomics | August 25 Price is up by 6.9% in the last 24h. |
|
Apollomics | August 24 Price is down by -6.3% in the last 24h. |
Apollomics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 11.9% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 25 | 0% | |
| Employee Recommend | 100 | 0% | |
| Business Outlook | 0 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 9 | N/A | |
| Stocktwits Mentions | 1 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 2K | 0.9% | |
| X Followers | 170 | 1.7% |
About Apollomics (APLM)
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
| Price | $22.08 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $68M |
| Year Range | $9 – $37 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Apollomics News
View more →
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in AsiaJune 24 - GlobeNewswire |
|
 |
Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsightAugust 19 - PRNewswire |
 |
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsightJuly 2 - PRNewswire |
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsightMay 14 - GlobeNewswire |
See Apollomics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for APLM, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEApollomics Earnings & Financial Performance
View all earnings →Apollomics Insider Trading Activity
View all →| No recent insider transactions on file. |
Apollomics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Apollomics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
DarioHealthDRIO |
$6.93 5.3% | $68M | 39 |
 |
Spero TherapeuticsSPRO |
$1.13 0.9% | $66M | 47 |
 |
LeonaBioLONA |
$6.86 0.0% | $65M | 55 |
 |
Pliant TherapeuticsPLRX |
$1.17 3.5% | $72M | 58 |
 |
INmune BioINMB |
$2.22 3.9% | $62M | 45 |
Explore Apollomics Data
Frequently Asked Questions: Apollomics (APLM)
Apollomics has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Apollomics (APLM) stock is $22.08 with a market cap of $68M.
As of today, Apollomics’s PE (Price to Earnings) ratio is —.
View the latest Apollomics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Apollomics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The APLM stock price chart above shows Apollomics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Apollomics technical analysis for RSI, moving averages, and more.
See the stocks similar to Apollomics section on this page for companies in the same industry ranked by market cap and AI Score.
